T-cell autoimmunity in multiple sclerosis. by Hohlfeld, R et al.
Concluding remarks 
Although a role for complement 
in tissue damage in diverse clinical 
situations is now widely accepted 9, 
no suitable therapeutic strategies for 
inhibiting complement have, until 
recently, been available. Basic re- 
search on membrane regulatory mol- 
ecules has focused attention on a new 
panel of agents that might prove ef- 
fective in therapy. With the enormous 
effort now being invested in the 
identification of active sites in these 
regulators, and in the design of more- 
active forms for use in vivo, it is 
likely that we will see inhibition of 
complement becoming an accepted 
clinical procedure. Perhaps the first 
instances where these inhibitors 
will find a niche is in the preven- 
tion of the iatrogenic injury that 
often accompanies cardiopulmon- 
ary bypass, as well as in other situ- 
ations where blood is exposed to 
foreign surfaces (perhaps including 
xenotransplantation). Here, short- 
term inhibition of complement may 
prove efficacious. However, if long- 
term inhibition of complement can 
be achieved safely and economi- 
cally, the inhibitors might find a 
much wider clinical role. This will 
undoubtedly require the design of 
cheaper inhibitors with improved 
activity and duration of action 
in vivo. This rapidly moving area 
should convince ven the most jaded 
of immunologists that complement 
research is no backwater but, rather, 
constitutes an exciting frontier of 
therapeutic mmunology. 
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T-cell autoimmunity in multiple sclerosis 
Reinhard Hohlfeld, Marco Londei, Luca Massacesi and Marco Salvetti 
Multiple sclerosis (MS) is one of 
the most frequent causes of neuro- 
logical impairment in young adults. 
Although the etiology of MS is still 
unknown, there is a general agree- 
ment that MS is an immune- 
mediated isease of the central ner- 
vous system in which myelin is 
destroyed. Recently, innovative im- 
munotherapies, ranging from in- 
hibitory cytokines or anti-cytokines 
to vaccination with autoreactive 
T cells or T-cell receptors (TCRs), 
have raised hopes for the first time 
that this disorder can be treated. 
These novel therapies are based on 
the principle that an autoimmune 
T-cell response is a central element 
in the immunopathogenesis of MS. 
Search for new autoantigens 
One of the central issues in basic 
MS research is the identification of 
the T-cell autoantigen(s). For many 
years, myelin basic protein (MBP) 
was considered to be the only major 
autoantigen for experimental uto- 
immune encephalomyelitis (EAE) 
Autoreactive T cells are crucial in 
the immunopathogenesis of mul- 
tiple sclerosis. As discussed at a 
recent meeting*, research in this 
area has provided the basis for 
innovative immunotherapies. 
and, accordingly, the only realistic 
candidate autoantigen for MS. De- 
tailed studies of the human T-cell 
response against MBP have revealed 
that multiple MBP epitopes are rec- 
ognized in the context of multiple 
restriction elements. Interestingly, in 
a minority of patients, >80% of the 
T-cell clones selected with whole 
MBP respond to a patient-specific 
cluster of immunodominant epi- 
topes. Such epitope clusters were 
noted in regions of the protein 
corresponding to residues 16-38, 
80-105, 108-131 and 131-153. In 
some patients, this reactivity pattern 
has remained remarkably stable over 
time (E. Meinl, Munich/Erlangen; 
M. Salvetti, Rome). 
*The meeting 'T-Cell Autoimmunity in 
Multiple Sclerosis' was held in Rome, 
Italy, 21-22 January 1995. 
© 1995, Elsevier Science Ltd 
In twins discordant for MS, the 
proliferative response to MBP ap- 
pears to be higher in the affected 
twin (M. Londei, London). Fur- 
thermore, using single-cell cyto- 
kine-production assays (T. Olsson, 
Stockholm), peripheral blood mono- 
nuclear cells (PBMCs) and cerebro- 
spinal fluid (CSF), cells from MS 
patients show increased responses 
to MBP and other myelin antigens, 
including proteolipid protein (PLP) 
and minor components such as my- 
elin oligodendrocyte glycoprotein 
(MOG), which are encephalito- 
genic in animals 1. In MS, the rela- 
tive pathogenetic role of MBP, PLP, 
MOG and other myelin antigens 
remains to established. 
One of the most interesting recent 
additions to the list of encephalito- 
genic autoantigens i $100[3, a cal- 
cium-binding protein of astroglia 2.
This is the first demonstration that 
a T-cell response against a non- 
myelin autoantigen can induce EAE. 
Not surprisingly, there is now an 
intense search for T-cell responses 
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against other myelin and nonmyelin 
autoantigens in MS (H. van Noort, 
Leiden). However, the situation is 
complicated by the possibility that 
an initial T-cell response against a 
myelin or nonmyelin autoantigen 
triggers a subsequent T- (and B-) cell 
response against other CNS auto- 
antigens (termed epitope spreading). 
Clues from TCR repertoire 
analyses 
As yet, it is not possible to dem- 
onstrate that human T cells specific 
for CNS autoantigens in vitro are 
pathogenic in vivo. TCR repertoire 
studies may provide an indirect 
means to identify potentially patho- 
genic responses. PCR amplification 
and sequence analysis of mRNA 
isolated from MS brain revealed 
TCR sequences similar to the TCRs 
of MBP-specific T-cell clones iso- 
lated from the blood of MS 
patients 3.Furthermore, interleukin 2
receptor (IL-2R)-positive T cells 
freshly isolated from the peripheral 
blood of an MS patient, but never 
exposed to MBP in vitro, expressed 
the same TCR sequence as T-cell 
clones isolated from the same patient 
by stimulation with MBP (E. Meinl). 
These observations suggest hat, at 
least in some MS patients, MBP is 
one of the autoantigens recognized 
in vivo. Clearly, this does not imply 
that MBP is the primary, or the 
only, autoantigen. 
MS lesions contain ~8 as well 
as ~[3 T cells 4. The ~8 T cells in 
chronic, active MS lesions express 
a predominant V82J83 gene re- 
arrangement 4. Experiments with 
T-cell lines derived from peripheral 
blood suggest that heat shock 
protein 70 (Hsp70) may select for 
T cells bearing the V82J~3 TCR 
(M. Salvetti). By contrast, mitogen- 
stimulated ~/8 T cells, cultured from 
the CSF of MS patients, predomi- 
nantly express V81 (G. DeLibero, 
Basle). Some of these CSF-derived 
~/~ T-cell clones kill glioblastoma 
and astrocytoma cell lines. 
New animal models 
It would be of great advantage if
human autoimmune reactions could 
be studied in animal models. This 
may eventually be achieved using 
mice with multiple transgenes, ex- 
pressing appropriate combinations 
of human cytokines, major histo- 
compatibility complex (MHC) and 
adhesion molecules, or with im- 
munodeficient mice reconstituted 
with human immune cells. Alterna- 
tively, it may be possible to estab- 
lish primate models in which hu- 
man T cells interact with host cells 
in vivo. As a first step in this direc- 
tion, it was demonstrated that a 
CD4 ÷ HLA-DRBI* 0301-restricted 
human T-cell clone can recognize 
MBP in vitro on PBMCs from dif- 
ferent rhesus monkeys expressing 
closely related rhesus MHC alleles 
(Mamu-DRBI*0305 and DRBI* 
0306) (B. t'Hart, Rijswijk; E. 
Meinl). In order to explore such 
'trans-species models' further, and 
to characterize encephalitogenic 
T cells in primates, it will be help- 
ful to establish novel EAE models 
in a variety of nonhuman primates, 
such as marmosets (L. Massacesi, 
Florence; B. t'Hart; A. Uccelli, 
Genoa). 
Role of cytokines: disease markers 
and targets for therapy? 
In the USA, the Food and Drug 
Administration (FDA) has recently 
approved a recombinant cytokine, 
interferon [3 (IFN-[3) lb, as the first 
immunomodulatory treatment for 
MS (Ref. 5). This decision has 
greatly stimulated interest in the 
role of cytokines in the pathogen- 
esis, diagnosis and therapy of MS. 
The exact mechanisms as to how 
IFN-[3 mitigates MS are poorly 
understood, but are probably re- 
lated to antagonistic effects on pro- 
inflammatory cytokines, such as 
IFN-y and tumour necrosis factor 
(TNF-~). Both of these cytokines 
are potent inducers of MHC class II 
antigens and adhesion molecules 
in target tissues. In MS patients 
(but not in healthy subjects), IFN-~ 
stimulates Ca 2÷ influx in CD4 ÷ 
T cells (G. Martino, Milan). This 
effect may be due to expression 
of a novel membrane channel, in- 
dicating that the T cells in MS are 
pre-activated. 
Two proinflammatory cytokines 
thought o play a particularly promi- 
nant role in the development of MS 
lesions are TNF-~ and TNF-[3 (lym- 
photoxin) (K. Selmaj, Lodz). Treat- 
ment with soluble p55 TNF recep- 
tor is effective in EAE, and will 
probably soon be tested in MS. 
Other treatment strategies rely on 
cytokines that induce a shift from 
the pathogenic T helper I (Thl)-like 
response to a dominant Th2-1ike 
immune reaction (T. Olsson). 
Not only are cytokines (and sol- 
uble cell adhesion molecules) po- 
tentially useful as therapeutic agents, 
but also as markers of disease 
activity (P. Rieckmann, G6ttingen; 
S. Jung, Wiirzbnrg; P. Gallo, Padua). 
Using a semiquantitative PCR tech- 
nique, it was demonstrated that 
there is a significant increase in the 
expression of TNF-c~ and TNF-[3 
in PBMCs prior to clinical relapse 
(P. Rieckmann). At the same time, 
there is often a decrease of poten- 
tially downregulatory c tokines uch 
as transforming growth factor [3 
(TGF-[3) and IL-10. 
Cell banks as tools for MS research 
It is hoped that, in the near 
future, most MS patients will be 
treated early in the course of their 
disease. Therefore, it will be in- 
creasingly difficult to collect fresh 
PBMCs from untreated patients. 
A repository of large amounts of 
frozen PBMCs collected through 
apheresis from untreated MS 
patients may help to circumvent 
this problem (L. Massacesi). 
Conclusion 
Although many important as- 
pects of the immunopathogenesis 
of MS have been elucidated, much 
remains to be learned. Future pro- 
gress will profit from continued 
national and multinational cooper- 
ation in the quest for improved 
therapies. 
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Targeting cancer with radiolabeled antibodies 
David M. Goldenberg, Steven M. Larson, Ralph A. Reisfeld 
and Jeffrey Schlom 
For many years, the strategies of 
cancer imaging and therapy with 
radioactive antibodies have made 
slow but steady strides in becoming 
new methods and agents in cancer 
management. Imaging with radio- 
labeled antibodies, termed radio- 
immunodetection (RAID), relies on 
a positive ratio between cpm at 
the target o cpm in adjacent, nor- 
mal tissues or circulating blood. 
In therapy with radioactive anti- 
bodies, termed radioimmunotherapy 
(RAIT), progress has been more 
modest because of the necessity to 
achieve high selective radiation doses 
to tumor sites yet maintain accept- 
able toxicity levels in normal organs, 
especially myelotoxicity. This article 
reports on the progress and pros- 
pects of using RAID and RAIT in 
the treatment ofcancer. 
Radiochemistry 
C.E Meares (Davis, CA) sum- 
marized recent progress in radio- 
chemical techniques, including new 
methods for effective pre-labeling 
prior to chelation of monoclonal 
antibodies (mAbs), in order to avoid 
the mixtures of macrocyclic om- 
pounds that may occur during post- 
conjugation labeling. O.A. Gansow 
(Bethesda, MD) discussed novel, 
dendrimer-based, polymetal che- 
lates, and their protein conjugates, 
with emphasis on enhancing the 
metal-ion-carrying capacity of mAbs 
for more-effective RAIT and for im- 
proved magnetic resonance imaging 
(MRI) by use of a polyamido- 
amine dendrimer as the intermediate 
A recent conference* focused on the 
advances, challenges and prospects 
of radioimmunodetection (RAID) 
and radioimmunotherapy (RAIT) 
of cancer. Emphasis was given to 
the underlying sciences of radio- 
chemistry, as well as its clinical 
and experimental pplications. 
carrier. Enhanced site-specific on- 
jugation of bifunctional chelating 
agents [diethylenetriamine petaacetic 
acids (DTPAs)] to a natural glyco- 
sylation site on the light chain 
of F(ab') 2 fragment of the anti- 
lymphoma mAb LL2 has been 
achieved (S.G. Govindan, Morris 
Plains, NJ). The same effect was 
demonstrated with an engineered, 
glycosylated version of the light 
chain of the anti-carcinoembryonic 
antigen (CEA) mAb IMMU-14 
[which had been humanized by 
grafting of the complementarity- 
determining regions (CDRs)]. Label- 
ing of this carbohydrate site with 
such diverse radionuclides as 90y, 
99mTc, 111In, 186Re and 188Re was 
achieved. L E Mausner (Upton, NY) 
introduced a new RAIT isotope, 
47Sc, considered to be useful be- 
cause of its favorable physical 
properties and its coordination 
chemistry for chelating to mAbs. 
The use of (x-particle mitters con- 
jugated with recombinant, hu- 
manized, anti-CD33 mAb M195, 
for the potential treatment of my- 
eloid leukemias, has produced 
*The 5th Conference onRadioimmuno- 
detection and Radioimmunotherapy of 
Cancer was held at Princeton, NJ, USA, 
on 6-8 October 1994. 
©1995, Elsevier Science Ltd 
encouraging results in animals 
(D.A. Scheinberg, New York, NY). 
A. Holmberg (Uppsala) reported 
that dextranation of antibodies im- 
proved the labeling efficacy of 
99mTc to 84-94%. 99roTe labeling 
of amide-derivatized single-stranded 
DNA for eventual use as single- 
stranded RNA and DNA oligo- 
nucleotides was described by D.J. 
Hnatowich (Worcester, MA). 
Experimental targeting 
Experimental studies of antibody 
targeting were introduced by D.J. 
Buchsbaum (Birmingham, AL), with 
emphasis on increasing tumor lo- 
calization and accretion of radio- 
labeled antibodies. These strategies 
included genetically engineered or 
biochemically modified antibodies, 
unlabeled antibody pre-dosing, anti- 
body cocktails, regional adminis- 
tration, and upregulation of target 
antigens by modifiers of biological 
responses. Methods described to 
increase the flow of blood through 
the tumor, or to increase its vascu- 
lar permeability, resulted in higher 
tumor accretion of radiolabeled anti- 
bodies, and included external ir- 
radiation, hyperthermia and vaso- 
active drugs. Bifunctional antibodies 
enhanced clearance of nontargeted 
antibody from normal tissues and 
blood, and resulted in higher tumor: 
nontumor ratios. 
Presentations on pre-targeting 
methods suggested that diverse 
methods for reducing targeting to 
normal tissues can enhance tumor 
radioimmunotherapy. D.B. Axworthy 
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